Founded by Jérôme Parc and Christophe Gaudin in 2016, Op2lysis has been created with the aim of developing the first medical treatment to reduce the severe sequelae that follow hemorrhagic stroke.
Op2lysis involves people with complementary skills and experiences including basic research and registration of pharmaceutical products.
Melina worked previously in a quarantine laboratory and in a Contract Research Organisation specialized in Central Nervous System. She has a strong and broad technical experience.
Christophe led the development of several cardiovascular blockbusters at Sanofi. He has a deep knowledge in clinical development.
Project Engineer, PhD student
Estelle developed the main in vitro models needed for the development of O2L-001. She joined the company early after the incorporation of the company and benefits from a specific convention for a doctorate in collaboration with the Inserm université de Caen research unit.
Regulatory affairs – non clinical development
Solène joined Op2Lysis with a strong experience as Toxicology study director in a Contract research Organization. Her job is now to prepare the non-clinical development of O2L-001.
Jerome spent more than 15 years on the development of O2L-001. He has a strong scientific knowledge and has a broad knowledge of the start-up environment.
Kathy Van Butsele
Regulatory affairs – CMC
Kathy has a prior experience in a small biotech company that growed and became a leader in the field of Women Health. She has a deep knowledge in chemicals, polymer and CMC (Chemicals, Manufacturing and Controls) for the development of O2L-001.